Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | PTGES | O14684 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22859643 | 0.78 | NOTUM (0.45) | GAAKMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL20868509 | 0.78 | NOTUM (0.45) | GAAKMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL28934829 | 0.75 | NOTUM (0.49) | GAAKMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL22480272 | 0.75 | NOTUM (0.43) | GAASMN1; SMN2ALDH1A1LMNAKDM4E | |
| SCHEMBL23059425 | 0.75 | NOTUM (0.43) | GAAKMT2ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL15964746 | 0.74 | NOTUM (0.50) | GAASMN1; SMN2ALDH1A1LMNAKDM4E | |
| SCHEMBL25884465 | 0.74 | NOTUM (0.42) | GAAKMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL24036185 | 0.74 | NOTUM (0.48) | GAAKMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL20857112 | 0.73 | NOTUM (0.47) | GAAKMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL29065096 | 0.73 | NOTUM (0.47) | GAAKMT2AALDH1A1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287341-A1 | GENETICALLY MODIFIED CELL LINES EXPRESSING AN EXOGENOUS SUBSTANCE AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287341-A1 | GENETICALLY MODIFIED CELL LINES EXPRESSING AN EXOGENOUS SUBSTANCE AND USES THEREOF | ZFX, XPA, CTCF | GAA 671/4885KMT2A 373/4885SMN1; SMN2 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.